Log In Sign up
The largest database of trusted experimental protocols

Anti flag

Manufactured by Fortis Life Sciences
Visit Supplier

The Anti-FLAG is a laboratory equipment used for protein purification and detection. It is designed to selectively bind and isolate proteins that have been engineered to contain a specific peptide tag, known as the FLAG tag. The Anti-FLAG provides a reliable and efficient method for purifying and identifying FLAG-tagged proteins from complex samples.

Automatically generated - may contain errors

Lab products found in correlation

Quickchange site directed mutagenesis kit, by Agilent Technologies (2 mentions) Phospho p42 44 mapk, by Cell Signaling Technology (1 mentions) Anti c myc tag, by Merck Group (1 mentions) Anti p19skp1, by BD (1 mentions) Anti rnf168, by Santa Cruz Biotechnology (1 mentions) Anti cdkn2a, by Santa Cruz Biotechnology (1 mentions) Anti cul1, by Thermo Fisher Scientific (1 mentions) Anti fbw7α, by Fortis Life Sciences (1 mentions) Anti trip12, by Fortis Life Sciences (1 mentions) Anti c myc y69, by Abcam (1 mentions) Anti mcl 1, by Cell Signaling Technology (1 mentions) Anti cyclin e, by Santa Cruz Biotechnology (1 mentions) Anti vinculin, by Merck Group (1 mentions) Anti gapdh, by Abcam (1 mentions) Anti α tubulin, by Abcam (1 mentions) Anti gfp, by Roche (1 mentions)

3 protocols using anti flag

1

Engineered RhoA Protein Variants

Check if the same lab product or an alternative is used in the 5 most similar protocols
DNA constructs of myc-tagged wild-type, p.Gly14Val, and p.Thr19Asn RhoA for mammalian expression were obtained from Missouri S&T cDNA Resource Center (www.cdna.org). The c.139G>A mutation (encoding p.Glu47Lys) was introduced into the wild-type RHOA sequence using the QuickChange site-directed mutagenesis kit (Agilent Technologies) as per manufacturer’s protocol, and primers listed in Supplementary Table 10. Other steps were performed as described above, with anti-Myc antibodies instead of anti-FLAG (Bethyl Laboratories, 1:500).
Vabres P., Sorlin A., Kholmanskikh S.S., Demeer B., St-Onge J., Duffourd Y., Kuentz P., Courcet J.B., Carmignac V., Garret P., Bessis D., Boute O., Bron A., Captier G., Carmi E., Devauchelle B., Geneviève D., Gondry-Jouet C., Guibaud L., Lafon A., Mathieu-Dramard M., Thevenon J., Dobyns W.B., Bernard G., Polubothu S., Faravelli F., Kinsler V.A., Thauvin C., Faivre L., Ross M.E, & Rivière J.B. (2019). Postzygotic inactivating mutations of RHOA cause a mosaic neuroectodermal syndrome. Nature genetics, 51(10), 1438-1441.
+ Open protocol
+ Expand
2

Western Blotting Antibody Panel

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies used for western blotting were anti-FBW7α (#A301-720A), and anti-TRIP12, 1:500 (#301-814A) from Bethyl, anti-FLAG, 1:5000 (#M2 clone), anti-HA-HRP-conjugate, 1:5000 (#A190108P), anti-c-MYC Tag, 1:500 (#clone4A6) HRP conjugated, and anti-vinculin, 1:1000 (#V9131) from Sigma, anti-GFP, 1:1000 (#11814460001, Roche), anti-Actin HRP-conjugate, 1:10,000 (#ab-49900), anti-GAPDH, 1;1000 (#ab9485), anti-c-MYC-Y69, 1:1000 (#ab-32072), and anti-α-tubulin, 1:2000 (#ab-7291) from Abcam, anti-CUL1, 1:1000 (#71-8700, Invitrogen), anti-p19Skp1, 1:1000 (#610530, BD Biosciences), anti-CyclinE, 1:1000 (#sc-481), and anti-RNF168, 1:1000 (#sc-101125) from Santa Cruz, anti-CDKN2a, 1:1000 (#4824), phospho-p42/44 MAPK, 1:1000 (#4376), and anti-MCL1, 1:1000 (#54539) from Cell signaling, anti-conjugated ubiquitin (FK2, 1:1000) (#BML-PW8810, Enzo life sciences), and anti-Lys11 linkage-specific, 1:500 (#MABS107), was from Millipore.
Khan O.M., Almagro J., Nelson J.K., Horswell S., Encheva V., Keyan K.S., Clurman B.E., Snijders A.P, & Behrens A. (2021). Proteasomal degradation of the tumour suppressor FBW7 requires branched ubiquitylation by TRIP12. Nature Communications, 12, 2043.
+ Open protocol
+ Expand
3

Engineered RhoA Protein Variants

Check if the same lab product or an alternative is used in the 5 most similar protocols
DNA constructs of myc-tagged wild-type, p.Gly14Val, and p.Thr19Asn RhoA for mammalian expression were obtained from Missouri S&T cDNA Resource Center (www.cdna.org). The c.139G>A mutation (encoding p.Glu47Lys) was introduced into the wild-type RHOA sequence using the QuickChange site-directed mutagenesis kit (Agilent Technologies) as per manufacturer’s protocol, and primers listed in Supplementary Table 10. Other steps were performed as described above, with anti-Myc antibodies instead of anti-FLAG (Bethyl Laboratories, 1:500).
Vabres P., Sorlin A., Kholmanskikh S.S., Demeer B., St-Onge J., Duffourd Y., Kuentz P., Courcet J.B., Carmignac V., Garret P., Bessis D., Boute O., Bron A., Captier G., Carmi E., Devauchelle B., Geneviève D., Gondry-Jouet C., Guibaud L., Lafon A., Mathieu-Dramard M., Thevenon J., Dobyns W.B., Bernard G., Polubothu S., Faravelli F., Kinsler V.A., Thauvin C., Faivre L., Ross M.E, & Rivière J.B. (2019). Postzygotic inactivating mutations of RHOA cause a mosaic neuroectodermal syndrome. Nature genetics, 51(10), 1438-1441.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!